Pharmasset, Idenix vets lead HBV company Antios to $25M series A

Founded by former executives of HCV companies that scored big exits, Antios Therapeutics Inc. (Atlanta, Ga.) raised a $25 million series A round to develop a cure for HBV.

Antios' co-founders include CEO Abel De La Rosa and CMO Douglas Mayers. De La Rosa comes from HCV company Pharmasset Inc., which seeded the HCV franchise of Gilead Sciences Inc. (NASDAQ:GILD) following its $11 billion acquisition in 2011...